黄婧, 邹俊娜, 任欢欢, 王珊*. 促进抗癌纳米药物肿瘤渗透的新型策略J. 药学学报, 2022,57(6): 1758-1770. doi: 10.16438/j.0513-4870.2021-1330
引用本文: 黄婧, 邹俊娜, 任欢欢, 王珊*. 促进抗癌纳米药物肿瘤渗透的新型策略J. 药学学报, 2022,57(6): 1758-1770. doi: 10.16438/j.0513-4870.2021-1330
HUANG Jing, ZOU Jun-na, REN Huan-huan, WANG Shan*. Novel strategies for promoting tumor penetration of anticancer nanomedicinesJ. Acta Pharmaceutica Sinica, 2022,57(6): 1758-1770. doi: 10.16438/j.0513-4870.2021-1330
Citation: HUANG Jing, ZOU Jun-na, REN Huan-huan, WANG Shan*. Novel strategies for promoting tumor penetration of anticancer nanomedicinesJ. Acta Pharmaceutica Sinica, 2022,57(6): 1758-1770. doi: 10.16438/j.0513-4870.2021-1330

促进抗癌纳米药物肿瘤渗透的新型策略

Novel strategies for promoting tumor penetration of anticancer nanomedicines

  • 摘要: 抗癌纳米药物在肿瘤治疗的临床应用上具有广泛和迫切的需求,但实体肿瘤中复杂的生物屏障一直是抗癌纳米药物向肿瘤实质渗透的主要障碍。依据传统的高渗透长滞留(enhanced permeability and retention,EPR)效应设计的纳米药物在肿瘤渗透性方面仍存在一定的局限性,亟需寻找其他纳米药物设计理论。因此,本文综述了促进抗癌纳米药物肿瘤渗透的两种新型策略—主动转胞吞策略和免疫细胞介导的肿瘤渗透策略。

     

    Abstract: There is a broad and urgent need for the clinical application of anticancer nanomedicine in tumor therapy, but the complex biological barrier in solid tumors has always been the main obstacle to infiltrating nanomedicine into the tumor. The traditional design of nanomedicine based on enhanced permeability and retention (EPR) effect still has some limitations in tumor permeability, it is urgent to find other design theories. Therefore, this review summarizes two novel strategies, active transcytosis and immune cell-mediated tumor penetration, for promoting tumor penetration of anticancer nanomedicine.

     

/

返回文章
返回